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Modern dose-intensive consolidation chemotherapy for
Patients and methods patients with acute myelogenous leukemia in first remission produces a median remission duration of 12-18 months; only Seventy-seven adult patients with newly diagnosed acute 20-44% of patients survive 5 years free of recurrence. [1] [2] [3] [4] [5] [6] [7] The myelogenous leukemia were enrolled on the ALP (Acute Leumechanism of relapse is proliferation of leukemia cells which kemia protocol) 5 study conducted by the UCLA School of survive induction and consolidation therapy. In order to proMedicine from November 1992 to May 1996. Data were analong leukemia-free survival, a variety of other post-remission lyzed as of 31 March 1997. Median follow-up from the time treatment regimens have been evaluated including myelosupof remission induction for surviving patients eligible for conpressive maintenance therapy, multiple and prolonged cycles solidation is 29 months (range, 10-52 months). This study of consolidation, and allogeneic bone marrow transplandesign was approved by the UCLA Human Subject Protection tation. 4, [8] [9] [10] [11] [12] Allogeneic bone marrow transplantation from a Committee and all patients provided written informed consent histocompatible HLA-matched sibling donor is available only to participate. to a limited group of younger patients. 13 Because of a high The diagnosis of acute myelogenous leukemia was made treatment-related mortality, the probability of survival after according to French-American-British (FAB) criteria. 23 De allogeneic transplant is similar to that which can be achieved novo acute myelogenous leukemia was defined if no docuby dose-intensive consolidation chemotherapy alone.
10, [14] [15] [16] mented hematologic abnormality was identified more than 2 Autologous bone marrow transplantation allows for the use of months before diagnosis. 3 Preleukemia was defined as ineffective hematopoiesis documented more than 2 months before the diagnosis of acute myelogenous leukemia by either an plained peripheral blood cytopenia.
3,10 Patients with leukemia additional hour. Cells were then swollen in a hypertonic solution of 0.4% potassium chloride for 15 min and fixed in Carsecondary to treatment for another malignancy were not eligible. Karyotype was classified as follows: (1) normal, ie dipnoy's fixative. After subsequent centrifugation and washing of cells with fresh fixative the cell suspension was applied to loid; (2) abnormal but favorable, ie t(8;21), or abnormalities of 16q; (3) abnormal and unfavorable, ie trisomy 8, abnorslides, banded with trypsin, and then stained with Giemsa to obtain metaphase analysis. 27 The remainder of the stem cell malities of chromosomes 5 and/or 7, any abnormality of chromosome 11, multiple (у3 abnormalities) or complex translocollection was cryopreserved daily in 10% dimethylsulfoxide by control-rate freezing and stored in the gas phase of liquid cation; and (4) abnormal all others.
3 Patients with acute promyelocytic leukemia with or without t (15;17) were not elinitrogen. Cell counts were performed using a Coulter counter (Coulter Electronics, Hialeah, FL, USA). A target mononuclear gible for this study. Seventy-seven patients received induction chemotherapy consisting of cytarabine, 100-200 mg/m 2 by cell dose of 5 × 10 8 /kg was used as an endpoint for collection. Samples were run on a FACScan flow cytometer (Becton continuous infusion for 5-7 days and idarubicin 10-13 mg/m 2 /day ×3 (70 patients) or daunorubicin, 45-Dickinson, San Jose, CA, USA) and after 1994, CD34-positive cells were defined with histogram analysis using the whole 60 mg/m 2 /day by intravenous bolus for 3 days (seven patients).
Patients received a second course of induction chemotherapy live-cell population. 22 A back-up bone marrow was collected in one patient due to a low peripheral blood progenitor cell on or after day 21 if residual acute leukemia was found in blood or bone marrow. Complete hematologic remission was collection.
Results, on the basis of intention to treat from the time of defined by the criteria of Ellison et al. 24 Sixty-three patients received high-dose cytarabine-based complete remission, were compared to an age-matched control group receiving consolidation chemotherapy only in a consolidation which was administered in a single course begun a median of 4 weeks after achieving complete study conducted from 1987 to 1992. 3, 28 Patients achieving remission were assigned to receive two to three courses of remission. Consolidation chemotherapy consisted of highdose cytarabine 2 g/m 2 administered as a 2-h i.v. infusion intensive consolidation treatment. Consolidation course 1 consisted of high-dose cytarabine, 2 g/m 2 i.v. over 1 h every every 12 h for 4 days and mitoxantrone 10 mg/m 2 by i.v. bolus/day for 3 days. Human recombinant G-CSF was admin-12 h for eight doses, days 1-4, and mitoxantrone 10-12 mg/m 2 /day for days 1-3. Course 2 consisted of mitoxanistered at 5 g/kg subcutaneously or i.v. or over 30 min beginning 1 day following completion of consolidation and controne 10-12 mg/m 2 for 3 days and etoposide 200 mg/m 2 /day for 5 days. Course 3 consisted of cytarabine 2 g/m 2 over 1 h tinued until the completion of stem cell leukapheresis.
Fifty-nine patients who achieved first complete remission every 12 h for eight doses, days 1-4, and daunorubicin 45 mg/m 2 /day for days 1-3. For historical patients у60 years were eligible for consolidation chemotherapy and autologous peripheral blood progenitor cell transplant on the basis of age of age, the consolidation chemotherapy dose was reduced to cytarabine 500 mg/m 2 , mitoxantrone to 7.5 mg/m 2 , etoposide Ͻ70, and no organ dysfunction. Forty-six eligible patients underwent autologous stem cell transplantation after preparato 100 mg/m 2 , and daunorubicin to 30 mg/m 2 .
28
Supportive care for granulocytopenic patients consisted of tive conditioning with 11.25 Gy total body irradiation given in five fractions over 2.5 days and cyclophosphamide, reverse isolation in single rooms and treatment with oral nonabsorbable antibiotics including nystatin and either norflox-60 mg/kg/day by i.v. infusion over 1 h daily for 2 days. Patients received mesna, 60 mg/kg/day by continuous i.v. acin or ciprofloxacin. Febrile granulocytopenic patients received imipenem or cefoperazone sulbactam, or other infusion at the start of cyclophosphamide and continued for 24 h after the last dose. After completion of transplantation, broad-spectrum antibacterial antibiotics. 29 Patients with documented or suspected fungal infections were treated with no maintenance therapy or other antileukemia therapy was administered until relapse. Toxicity was scored according to empiric amphotericin B or fluconazole. Random or single donor platelet transfusions were administered to maintain a standard criteria. 25 platelet count у10 × 10 9 /l. Erythrocytes were transfused to maintain an hematocrit у27%.
Progenitor cell collection and processing
Progenitor cell apheresis was begun after an absolute neutroStatistical analysis phil count of Ͼ1500 mm −3 was achieved during the recovery phase from consolidation therapy. Continuous-flow leukapheresis was performed daily on weekdays with a Cobe Spectra
The date of diagnosis of AML and the date of remission were defined by the date of the diagnostic bone marrow studies. (Cobe, Lakewood, CO, USA) until a total nucleated cell count of у3 × 10 8 /kg and/or CD34 cell count у1 × 10 6 /kg was Patients were analyzed for overall survival as well as leukemia-free survival (LFS) from the time of remission by the proobtained. Blood volume processed per run was 10 l at a flow rate of 50-70 ml/min. Platelet and erythrocyte fractions were duct-limit method of Kaplan and Meier. 30 Univariate comparisons of patients undergoing induction and consolidation reinfused continuously. The final apheresis product was centrifuged at 400 g concentrated to 10 8 cells/mm 3 , and cooled chemotherapy were performed using Fisher's exact test and the Wilcoxon rank-sum test. 31 Summary estimates included to 4°C. Cytogenetics were analyzed on an aliquot of the leukapheresis collection in all patients undergoing progenitor cell survival fractions ± two times the standard error for 95% confidence intervals for median survival time. 30, 31 Survival curves procurement by taking 0.01-0.03 ml of the stem cell suspension sample and placing it directly into flasks containing 10 ml were compared using the log rank test. Prognostic factors for achieving complete remission were analyzed using logistic RPMI 1640 culture medium supplemented with 1 ml cell growth factor. 26 After remaining in culture for 24-48 h, two regression. Prognostic factors for survival and leukemia-free survival (LFS) were evaluated using the Cox regression analydrops of ethidium bromide (0.01 mg/ml) were added to each flask for 30 min. One drop of colcemid (10 g/cm 3 ) (Life sis. Analyses were performed using the BMDP statistical package.
31 P values were two-sided throughout. Technologies, Grand Island, NY, USA) was added for an
Results
blood progenitor cell transplant included serious organ toxicity in six patients with treatment-related mortality in two patients due to pneumonitis and infection, respectively (see Fifty-nine patients under the age of 70 received consolidation chemotherapy with high-dose cytarabine and rHuG-CSF for Table 2 ). Disease-free survival and survival from remission for patients eligible for autologous transplantation are indicated the purpose of in vivo purging and procuring autologous progenitor cells for transplantation. The median duration of folin Figures 1 and 2 , respectively. Thirty-one of the 59 patients (52%) remain alive with 27 in continued first remission from low-up for surviving patients from the time of complete remission is 29 months (range, 10-52 months). Patient charac-7 to 50 months. Median remission duration at the time of analysis is 12 months (range, 2-50 months) and actuarial leuteristics at the time of consolidation chemotherapy are described in Table 1 . Toxicity of consolidation chemotherapy kemia-free survival at 3 years is 42 ± 14%. Median survival from remission is 14 months (range, 3-46 months) and actuincluded serious neurotoxicity due to high-dose cytarabine in one patient and treatment-related death in two due to infecarial survival from remission at 3 years is 47 ± 14%. Twentyseven (46%) have relapsed with an actuarial risk of relapse at tion and multiorgan system failure, respectively. Eight patients did not undergo autologous peripheral blood progenitor cell 3 years of 54 ± 15% (median time to relapse 8 months). Sixteen patients received further intensive chemotherapy and five collection due to prolonged infection (two patients), excessive toxicity related to consolidation (one patient), death due to achieved a second remission. Five underwent allogeneic bone marrow transplant but none are long-term survivors. Median consolidation (two patients) or early relapse (three patients). Five other patients did not undergo transplant due to patient survival after relapse was 4 months (range, Ͻ1-37+ months).
Of the 46 patients who actually underwent autologous periphrefusal (two patients), lack of insurance coverage and inadequate progenitor cell collection (one patient each); one eral blood progenitor cell transplant, median disease-free and overall survival are 12 and 15 months, respectively. The 3-patient elected to undergo allogeneic bone marrow transplantation. Results of all 59 patients are included in analysis of year actuarial disease-free survival from remission for the transplant patients is 41 ± 16%. remission duration, disease-free survival and survival on the basis of intention to treat. A median of four collections (range, Age was a predictive factor for median duration of leukemia-free survival. The median leukemia-free survival for all 29 2-15) were required to procure a median of 7 × 10 8 total mononuclear cells/kg (range, 3-15 × 10 8 /kg). After 1994, patients over age 45 (21 of whom underwent transplant) vs 30 patients age р45 years (25 of whom underwent transplant) CD34-positive cells were measured in the collections from 19 patients; the median number of CD34-positive progenitor cells were 9 months and 15 months, respectively (P = 0.06). The actuarial disease-free survival 3 years from complete procured was 5.6 × 10 6 /kg (range, 0.3-30 × 10 6 /kg). After transplantation, the median time to neutrophil Ͼ500 mm −3 remission for all eligible patients over the age of 45 is 25 ± 19% as opposed to 56 ± 18% for patients р45 years of and untransfused platelet Ͼ20 000 mm −3 were 15 days (range, 11-36 days) and 15 days (range, 5-253+ days), respectively. age (P = 0.06). The actuarial risk of relapse at 3 years for patients age Ͼ45 is 70% compared with 42% for younger One patient received rHuG-CSF on day +21 following transplant to hasten hematopoietic recovery; he achieved neutropatients (P = 0.18). Ten of 16 eligible patients over age 60 underwent transplant; the actuarial disease-free survival for phil recovery 2 days later. Another patient received a backup bone marrow infusion on day +35 for delayed hematologic this group was considerably lower, 20 ± 22%. In multivariate analysis of leukemia-free survival, other prerecovery. Complications related to autologous peripheral treatment characteristics such as the presence of a chromosomal abnormality, AML subtype, pretreatment peripheral blood count, and history of antecedent hematologic disorder 
Figure 1
Probability of leukemia-free survival for 59 patients receiving high-dose cytarabine-based consolidation chemotherapy and eligible for autologous PBPC transplant.
ary toxicity, although uncommon, was more prevalent in Even in younger patients, however, the major cause of treatment failure after high-dose cytarabine-based consolidation patients over age 45 than in younger patients (P = 0.02).
Results for the 59 patients on the present study were comchemotherapy is leukemia relapse. Intensive chemoradiotherapy followed by transplantation of allogeneic bone marrow is pared to an age-matched historical control group (ALP4) with similar pretreatment characteristics assigned to receive highassociated with a significantly lower risk of relapse at the expense of a high risk of treatment-related morbidity and mordose consolidation chemotherapy without autologous transplantation (Table 3) . Patients enrolled on the ALP4 study had tality. 10, 11, 14, 15 Transplantation with autologous bone marrow allows the administration of intensive myeloablative cona remission duration of 9 months (range, 2-112 months). The actuarial disease-free survival and overall survival 3 years ditioning followed by the infusion of patients' previously collected and cryopreserved bone marrow. [17] [18] [19] [20] 36 A potential from remission were 22 ± 11% and 38 ± 13%, respectively. Results for leukemia-free survival were statistically significoncern is the application of myeloablative therapy to a population of patients with adverse prognostic features such as cantly improved with the current regimen (ALP5) compared to the ALP4 group (P = 0.05), but no significant difference has advanced age or history of antecedent hematologic disturbance. Another major concern with the use of autologous bone yet been achieved in remission duration or overall survival. marrow is the possible contamination with clonogenic leukemia cells. In order to overcome the risk of infusing residual leukemia cells in the bone marrow product, most studies of Discussion autologous transplant have utilized ex vivo bone marrow purging. 7, 19, 37 Incubation of cryopreserved bone marrow with Post-remission therapy is required to prevent or delay relapse in patients with acute myelogenous leukemia, but the optimal cytotoxic agents is complicated by prolonged myelosuppression, increasing the risk of treatment-related morbidity and form of treatment is uncertain. Use of one to several courses of intensive high-dose cytarabine-based consolidation therapy mortality, particularly in older patients or patients with a history of preleukemia. For these reasons we chose to evaluate may obviate the need for prolonged maintenance and has been shown to produce improved leukemia-free survival for a system of in vivo purging using autologous peripheral blood progenitor cells procured after high-dose cytarabine-based younger patients. 3, 4, [32] [33] [34] [35] Because adverse events related to consolidation are unequally distributed and occur primarily in consolidation chemotherapy, rather than bone marrow, in order to facilitate rapid hematopoietic recovery with minian older age group, and because older patients have a greater risk of relapse, high-dose consolidation chemotherapy alone mal toxicity.
36,38
The objective of this analysis was to determine the feasihas not been shown to produce an improved leukemia-free survival in older patients. 3, 4 bility, toxicity, and efficacy of autologous peripheral blood Probability of survival for 59 patients receiving high-dose cytarabine-based consolidation chemotherapy and eligible for autologous PBPC transplant.
progenitor cell transplantation following myeloablative chemo-radiotherapy for a representative group of adults with acute myelogenous leukemia in first complete remission. Fifty- autologous progenitor cell transplant. Thus, we were able to Antecedent hematologic disorder (%) 14 (25) proceed with the intended form of therapy in many patients ies of autologous bone marrow transplant. [17] [18] [19] [20] [36] [37] [38] [39] bility of autologous PBPC transplant in an older population.
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After a median follow-up from remission of 26 months, 30
patients (51%) remain in continued remission for a 3-year
actuarial leukemia-free survival of 42 ± 15%; further follow-M7 2 up will be required to determine whether this difference will persist and whether an improvement in overall survival can be demonstrated. Age was a significant adverse prognostic factor We thank Linda Rodman for preparation and typing of the manuscript. suggesting that despite good tolerance, high-dose chemoradiotherapy and autologous transplant could not overcome the effect of disease biology on outcome.
Most studies of autologous bone marrow transplant involve References the use of ex vivo purged marrow as a source of hematopo-difference in overall survival can be demonstrated. 15, 16 York, 1990, pp 313-322. relapse at 2 years were 49 and 44%, respectively.
